Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2016-06-08

Clinical Trial Update: Feasibility Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent [Phase 2]

View source ↗

Summary

This is a Phase 2 feasibility study of the FORTITUDE bioresorbable drug-eluting coronary stent by Amaranth Medical, with the trial status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • FORTITUDE Bioresorbable Drug-Eluting Coronary Stent

Snippet

Sponsor: Amaranth Medical Inc. | Conditions: Coronary Artery Disease, Myocardial Ischemia | Phase 2 | Status: UNKNOWN